[Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib]

Rinsho Ketsueki. 2020;61(10):1508-1510. doi: 10.11406/rinketsu.61.1508.
[Article in Japanese]

Abstract

Central nervous system (CNS) involvement in mantle cell lymphoma (MCL) is uncommon. Here we present the case of a 70-year-old male patient who was diagnosed with classic MCL in 2015. The patient achieved complete remission (CR) in 2017 but relapsed with CNS involvement in 2019. He entered a deep coma and was treated with ibrutinib (560 mg daily) via nasogastric tube. He regained full consciousness after 15 days, and the presence of lymphoma cells in his cerebrospinal fluid disappeared 3 months later. We believe that ibrutinib administration via nasogastric tube is effective for MCL patients with CNS relapse.

Keywords: Central nervous system involvement; Ibrutinib; Mantle cell lymphoma; Nasogastric tube.

Publication types

  • Case Reports

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Aged
  • Central Nervous System
  • Central Nervous System Neoplasms* / drug therapy
  • Humans
  • Lymphoma, Mantle-Cell* / drug therapy
  • Male
  • Neoplasm Recurrence, Local
  • Piperidines / therapeutic use*

Substances

  • Piperidines
  • ibrutinib
  • Adenine